The stock of Cytokinetics Inc (CYTK) has seen a 1.09% increase in the past week, with a 7.21% gain in the past month, and a -13.44% decrease in the past quarter. The volatility ratio for the week is 3.87%, and the volatility levels for the past 30 days are at 3.66% for CYTK. The simple moving average for the past 20 days is 3.82% for CYTK’s stock, with a -0.95% simple moving average for the past 200 days.
Is It Worth Investing in Cytokinetics Inc (NASDAQ: CYTK) Right Now?
The 36-month beta value for CYTK is also noteworthy at 0.75. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CYTK is 110.89M, and at present, short sellers hold a 15.67% of that float. The average trading volume of CYTK on July 24, 2024 was 2.03M shares.
CYTK) stock’s latest price update
Cytokinetics Inc (NASDAQ: CYTK)’s stock price has plunge by -0.07relation to previous closing price of 57.42. Nevertheless, the company has seen a 1.09% surge in its stock price over the last five trading sessions. globenewswire.com reported 2024-07-03 that SOUTH SAN FRANCISCO, Calif., July 03, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 28, 2024 it granted stock options to purchase an aggregate of 48,453 shares of common stock, 31,460 restricted stock units (RSUs), and 5,537 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in June 2024, as a material inducement to their employment.
Analysts’ Opinion of CYTK
Many brokerage firms have already submitted their reports for CYTK stocks, with UBS repeating the rating for CYTK by listing it as a “Neutral.” The predicted price for CYTK in the upcoming period, according to UBS is $92 based on the research report published on January 24, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CYTK reach a price target of $90, previously predicting the price at $60. The rating they have provided for CYTK stocks is “Equal-Weight” according to the report published on January 05th, 2024.
Goldman gave a rating of “Buy” to CYTK, setting the target price at $50 in the report published on November 09th of the previous year.
CYTK Trading at 4.87% from the 50-Day Moving Average
After a stumble in the market that brought CYTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.95% of loss for the given period.
Volatility was left at 3.66%, however, over the last 30 days, the volatility rate increased by 3.87%, as shares surge +6.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.37% lower at present.
During the last 5 trading sessions, CYTK rose by +1.09%, which changed the moving average for the period of 200-days by +112.13% in comparison to the 20-day moving average, which settled at $55.44. In addition, Cytokinetics Inc saw -31.27% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYTK starting from Malik Fady Ibraham, who sale 7,300 shares at the price of $57.02 back on Jul 23 ’24. After this action, Malik Fady Ibraham now owns 129,004 shares of Cytokinetics Inc, valued at $416,246 using the latest closing price.
PARSHALL B LYNNE, the Director of Cytokinetics Inc, sale 5,000 shares at $55.82 during a trade that took place back on Jul 15 ’24, which means that PARSHALL B LYNNE is holding 20,600 shares at $279,100 based on the most recent closing price.
Stock Fundamentals for CYTK
Current profitability levels for the company are sitting at:
- -132.72 for the present operating margin
- -45.48 for the gross margin
The net margin for Cytokinetics Inc stands at -141.42. The total capital return value is set at -0.69.
Based on Cytokinetics Inc (CYTK), the company’s capital structure generated 2.65 points at debt to capital in total, while cash flow to debt ratio is standing at -0.66. The debt to equity ratio resting at -1.61. The interest coverage ratio of the stock is -8.06.
Currently, EBITDA for the company is -484.31 million with net debt to EBITDA at -1.33. When we switch over and look at the enterprise to sales, we see a ratio of 1922.61. The receivables turnover for the company is 4.5for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.19.
Conclusion
In summary, Cytokinetics Inc (CYTK) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
